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ABSTRACT Limb-girdle muscular dystrophy type 2A (LGMD2A) is an autosomal recessive disorder characterized by selective
atrophy of the proximal limb muscles. Its occurrence is correlated, in a large number of patients, with defects in the human CAPN3
gene, a gene that encodes the skeletal muscle-specific member of the calpain family, calpain 3 (or p94). Because calpain 3 is
difficult to study due to its rapid autolysis, we have developed amolecular model of calpain 3 based on the recently reported crystal
structures of m-calpain and on the high-sequence homology between p94 and m-calpain (47% sequence identity). On the basis
of this model, it was possible to explain many LGMD2A point mutations in terms of calpain 3 inactivation, supporting the idea that
loss of calpain 3 activity is responsible for the disease. The majority of the LGMD2A mutations appear to affect domain/domain
interaction, which may be critical in the assembly and the activation of the multi-domain calpain 3. In particular, we suggest that
the flexibility of protease domain I in calpain 3 may play a critical role in the functionality of calpain 3. In support of the model, some
clinically observed calpain 3 mutations were generated and analyzed in recombinant m-calpain. Mutations of residues forming
intramolecular domain contacts caused the expected loss of activity, but mutations of some surface residues had no effect on
activity, implying that these residues in calpain 3 may interact in vivo with other target molecules. These results contribute to an
understanding of structure-function relationships and of pathogenesis in calpain 3.
INTRODUCTION
The calpains are a family of intracellular cysteine proteases
(Sorimachi et al., 1997; Ono et al., 1999; Carafoli et al.,
1998; Belcastro et al., 1998). The two calpains first discov-
ered, - and m-calpain, are ubiquitously expressed in mam-
malian tissues. These enzymes are strictly Ca2 dependent,
and are thought to be involved in many essential cellular
functions involving Ca2 signaling. They consist of a large
or catalytic subunit (80 kDa, encoded by the closely related
genes CAPN1 and CAPN2, respectively), and a common
regulatory subunit (28 kDa, CAPN4). The large subunits are
divided into four structural domains (I to IV) and the small
subunit contains domains V and VI. Crystal structures of
m-calpain in the absence of Ca2 have recently been de-
scribed (Hosfield et al., 1999, Strobl et al., 2000).
Calpain 3, also commonly known as p94, is a muscle-
specific form of calpain that appears to consist only of a
94-kDa catalytic subunit without a small subunit, requires
little or no Ca2 for activity, and is characterized by rapid
and complete autolysis, with a half-life of 10 min (Sori-
machi et al., 1993; Kinbara et al., 1998). The amino acid
sequences of -calpain, m-calpain, and calpain 3 are50%
identical, and well-aligned throughout the whole sequence,
but calpain 3 possesses three additional segments, known as
NS at the N terminus, IS1 in domain II, and IS2 between
domains III and IV.
Mutations in CAPN3 have been shown to be responsible
for limb-girdle muscular dystrophy type 2A (LGMD2A), or
calpainopathy (Richard et al., 1995, 1999), and more than
100 independent pathogenic mutations have been reported
(Richard et al., 1997, 1999; Fardeau et al., 1996; Chou et al.,
1999; Minami et al., 1999). It is assumed that all of these
mutations abolish, or at least reduce, the function of calpain
3, but this has not been demonstrated in every case (Ono et
al., 1999). Some of the mutations will obviously abolish
protein function, such as nonsense, insertion/deletion, or
splice-site mutations, but approximately half are missense
mutations, single amino acid substitutions, the effect of
which on calpain 3 activity is not immediately predictable.
For several of these missense mutations, it was shown that
the mutant calpain 3 was no longer able to hydrolyse fodrin,
but in some cases was still able to autolyse (Ono et al.,
1998; Sorimachi et al., 2000).
Because direct quantitative analysis of calpain 3 function
is difficult due to its rapid autolysis and, consequently,
extremely short half-life, we have attempted to predict the
effects of single amino acid substitutions in calpain 3 using
two alternative approaches. We have constructed a molec-
ular model of calpain 3 using m-calpain as a template,
making the assumption, based on the high level of sequence
identity, that these structures should be very similar, despite
the presence in calpain 3 of additional sequences and its
apparent lack of a small subunit. The clinically significant
mutations are scattered along the whole sequence, including
some within the IS1 and IS2 regions, but most occur in
regions that can be modeled onto m-calpain. The model-
ing is also of great interest because many of the clinically
observed mutations with pathogenic consequences in-
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volve amino acid residues that are highly conserved
throughout all mammalian calpains (Richard et al.,
1999). To provide experimental support for the modeling
studies and to assess directly mutation effects on enzyme
activity, several mutations that appear to be pathogenic in
calpain 3 have been generated in the corresponding po-
sitions in m-calpain.
A direct correlation of clinical observations with the
effects of mutation on the activity of the enzyme is not
expected to be possible in every case. Each of the many
distinct calpain 3 mutations has been observed only in one
or a few patients, and the mutations usually occur in com-
pound heterozygotes (i.e., where the other calpain 3 allele
has a different mutation). Nonetheless, we have attempted
to interpret the mutations with the assumption that a reduc-
tion or complete loss of calpain activity is a cause of
LGMD2A.
MATERIALS AND METHODS
Modeling and structural analysis
The initial backbone threading was achieved using comparative protein
modeling methods as implemented in the automated protein modeling
server Swiss-Model (Peitsch, 1996). The protein sequence of calpain 3 was
mapped to the coordinates of the rat m-calpain large subunit (Hosfield et
al., 1999). The resulting model was visually inspected and manually
corrected for any obvious defects, and then energy-minimized using pro-
gram package Sybyl (Tripos, St. Louis, MO). The process of extensive
energy minimization was allowed to continue until it reached convergence.
For structural analysis of calpain 3 mutations, the amino acids with
mutations that are implicated in LGMD2A were converted in the model to
their mutated forms, and the mutated calpain 3 models were then briefly
energy-minimized again (200 cycles). All resulting mutant models were
visually checked and analyzed. They were superimposed with the known
crystal structures of rat and human m-calpains (Hosfield et al., 1999; Strobl
et al., 2000). Model quality was assessed using Procheck (Laskowski et al.,
1993) and figures were prepared with Molscript (Kraulis, 1991).
Site-directed mutagenesis and activity
measurement
Several point mutations were made in m-calpain, to correspond to
calpain 3 mutations reported in LGMD2A patients. Site-directed mu-
tagenesis was performed with antisense primers on single-stranded
DNA derived from pET-24-m-80k-CHis6 (Elce et al., 1995). In each
case, the presence of the mutation was confirmed by restriction diges-
tion and DNA sequencing.
Expression, purification, and activity assay of mutant m-calpains were
performed as previously described (Elce et al., 1995; Dutt et al., 2000).
RESULTS AND DISCUSSION
An alignment of the amino acid sequences of the rat m-
calpain large subunit and human calpain 3 is shown in Fig.
1. To avoid confusion in the numbering of residues, all
positions are described in terms of the human calpain 3
amino acid sequence. Where necessary in the text, rat
m-calpain amino acid residue numbers are given in italics.
Model of calpain 3
As expected, the modeled calpain 3 structure is very similar
to that of m-calpain (Fig. 2) in the absence of Ca2. The
r.m.s. deviations for all corresponding C between calpain
3 and m-calpain is 1.33 Å. The model is unavoidably less
certain in the regions of IS1 and IS2 sequences, which
represent insertions of 60 and 64 residues, respectively,
when compared with the large subunit of m-calpain. Due to
lack of homologous structural template, the NS region was
not modeled. The insertions are clearly important for two
reasons. In the first place, clinically deleterious mutations,
P319L in IS1, and S606L and Q638P in IS2, have been
observed in these regions. Secondly, these regions are sub-
ject to alternative splicing, so that mutations therein might
affect some or all of the possible isoforms. The work
described here was restricted to residues that can be mapped
onto m-calpain, and therefore refers only to the predominant
mature form of calpain 3 in skeletal muscle.
In the model, the two inserted sequences, IS1 and IS2,
protrude out of the globular core structure, and can largely
be accommodated without disruption of the overall fold.
Most of IS1 (G269-G329) modeled as a two-stranded
-sheet and a coil. However, residues D267-M272, at the
beginning of IS1, form a loop in the calpain 3 model,
oriented into the protein toward domain I, that is expected to
affect the activity of the enzyme. The IS2 region (S589-
Q653) was resolved in the model as two separate -helices.
These helices are in the middle of the transducer arm
(D514-F538), which, in m-calpain, was proposed to com-
municate Ca2-induced changes in domain IV to the rest of
the molecule. Introduction of IS2 into this arm may have the
effect similar to Ca2-induced change to this part of the
structure and hence contribute to the very low Ca2 require-
ment for the activation of calpain 3.
In m-calpain, it was immediately obvious from the x-ray
structures that domains I and II, although they already have
many contacts, must move closer together after Ca2-in-
duced activation of the enzyme to assemble the active site.
Movement of domain I is thought to be facilitated by the
autolysis of the N terminus, and movements of both do-
mains I and II, (involving or mediated by domain III), are
thought to occur in response to Ca2-induced conforma-
tional changes in domains IV and VI (Hosfield et al., 1999).
Although LGMD2A-associated mutations are observed
throughout the sequence, many mutations are clustered in
only three areas, all of which might affect domain move-
ment (Fig. 3). The three clusters are located at K207-G234,
E435-R448, and S479-I502. The main contact of domain I
with domain III involves a group of -helices in domain I
containing the first cluster of mutations, K207-G234, that
are in close proximity to a variety of distinct regions in
domain III including a loop which contains the third cluster
of mutations, S479-I502. It is likely that changes in this
interaction will affect the flexibility of domain I, and there-
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fore affect assembly of the active site. The second cluster of
mutations, E435-R448, is located on a loop of domain III
that has interactions with domain IV, and is expected to be
involved in the communication of Ca2-induced conforma-
tional change throughout these domains.
Calpain 3-related mutations expressed
in m-calpain
For logistical reasons, only six calpain 3 mutations were
directly analyzed by mutagenesis in m-calpain. These six
m-calpain mutants, each incorporating a single amino acid
substitution corresponding to a known pathogenic mutation
in calpain 3, were created by mutagenesis, expressed in
Escherichia coli, purified, and their specific activities mea-
sured (Table 1). All mutants were well expressed as soluble
heterodimers, which we generally take as an indication that
their folding proceeded normally. Of these, four mutant
enzymes had very low, but not zero, specific activities,
consistent with a pathogenic role in LGMD2A; but two,
R448H and D705G, were fully active, so that their apparent
pathogenicity is not immediately understood. The effects of
these m-calpain mutations will be discussed together with
the calpain 3 model in the following sections.
Domain I
There are 18 mutations within this domain (Fig. 4B), and,
except for S86F, they are mostly associated with a relatively
mild course of the disease. The mutations D77N and S86F
FIGURE 1 The primary sequence alignment of large subunit of m-calpain (upper sequence) and calpain 3 (lower sequence) shows a high degree of
homology between these two proteins (47% identity). The amino acids implicated in LGMD2A are seen throughout the sequence of calpain 3 (purple). The
regions where mutations affect domain-domain interaction and assembly are grouped into three distinct clusters (yellow bar). Each mutation residue is
highlighted in bold letters, below the corresponding amino acids.
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may influence the positioning of the N terminus of the
enzyme; S86F clearly introduces a major steric disturbance,
and clinically is one of the most severe missense mutations.
The residues R118 and C137 are very close to portions of
domain II, and their mutations, R118G and C137R, intro-
duce major changes in size and charge, which would disrupt
domain I/domain II interaction in the resting state, and
would also affect assembly of the active site during enzyme
activation. The m-calpain mutation, R94G, corresponding to
R118G, was expressed in E. coli, and had only 5% of
wild-type activity (Table 1). The effects of several other
mutations in domain I are more difficult to explain. For
instance, the mutations V98I and I162L both exchange two
very similar hydrophobic residues, without any obvious
effects on the structure. It is possible that these residues
FIGURE 2 Superimposition of calpain 3 model (green) and the crystal
structure of m-calpain (blue) by C alignment. The modeled structure of
calpain 3 displays a high similarity to m-calpain with the exception of two
insertion regions, IS1 and IS2.
FIGURE 3 Three mutation clusters identified in the primary structure of
calpain 3 are shown as colored regions in the corresponding model. The
mutation clusters in domain I (red) and domain III (yellow) share a large
interface and are expected to reduce the rigidity of domain I to facilitate
calpain 3 inactivation. The third mutation cluster in domain III (green) may
have an effect on domain III-domain IV interaction. The two insertion
regions, IS1 and IS2, are located in domain II and in the linker region of
domain III, respectively (light blue).
Table 1 Mutations in rat m-calpain
Actual mutation
in rat
m-Calpain
Corresponding
mutation in
calpain 3
Expression level
(wild type, %)*
Specific activity
(wild type, %)†
R94G R118G 100 5
E193K E217K 100 5
G198R G222R 100 10
E202K E226K 100 5
R375H R448H 100 100
D585G D705G 100 100
*Expression levels of the mutated 80-kDa m-calpain subunits were esti-
mated by immunoblotting and expressed as a percentage of wild-type
m-calpain.
†Specific activities of the purified enzymes were measured as described
(Dutt et al., 2000) and expressed as a percentage of wild-type m-calpain.
Each purification was performed only once.
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affect either folding of the enzyme, or its interactions with
cellular targets.
Eight of the domain I mutations are found, however, in
the cluster K207-G234 (Fig. 3), which makes many contacts
with a loop in domain III, and this loop itself contains the
third cluster of mutations (S479-I502). The E217K, G222R,
and E226K mutations were bacterially expressed in the
corresponding positions in m-calpain, and all had very weak
activity (Table 1). This is consistent with the model because
E217, for example, is close to K494 in domain III, and E226
and E229 are close to R541 (which does not belong to the
third cluster); these mutations in calpain 3 would be ex-
pected to disrupt salt links between domains I and III. In
agreement with those observations, it may be noted that the
R541W mutation in domain III is also associated with the
disease. G222 is close to L495, so the mutation G222R is
likely to disturb the local interactions.
Domain II
This domain contains relatively few pathogenic mutations
(Fig. 4 A), but most of them are readily interpretable.
H334QY abolishes the histidine residue of the catalytic
triad, which will drastically reduce activity. Interestingly,
the patient carrying this H334Q mutation is a compound
heterozygote with a null mutation, so that any calpain 3
activity must derive from the H334Q allele. This patient
FIGURE 4 Clustered mutation sites in the calpain 3 model. A, B, C, and D are the regions of domains II, I, III, and IV, respectively. The majority of
mutations implicated in the development of LGMD2A are located at the domain interfaces with an especially high occurrence at the domain I-domain III
contact region.
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shows a relatively mild course of disease. The related
H262A mutation in m-calpain had been made previously,
and was inactive (Arthur et al., 1995). The mutation Y336N
alters a set of direct and indirect contacts that affect the
orientation and electrostatic properties both of H334 and of
W360. The mutation W360C is of interest because this
tryptophan residue has frequently been studied in cysteine
proteases, and may have two roles in calpain. It appears to
affect the active-site triad directly in many cysteine pro-
teases, and it may be additionally important in m-calpain in
the relative motions of domain I and II (Hosfield et al.,
1999). Several patients homozygous for the W360C muta-
tion have been described, and show a slightly more severe
disease development than those with H334Q. In m-calpain
the corresponding W288Y mutation gave an enzyme that
was very weakly active (Arthur et al., 1995).
Domain III
As mentioned earlier, most of the mutations in domain III
lie in the region of contact between domain III and domain
I (Figs. 3 and 4 C). Four residues in this region are directly
involved in salt links with residues in domain I, so that the
pathogenic effects of their mutations (E435K, R493W,
R541W, R572WQ), can be readily understood in terms of
disruption of salt links and of communication between these
two domains. The mutations R440W, G441D, and G445R
are all located at the interface between domains III and IV,
and involve an alteration in charge. These mutations must
also disrupt communication between Ca2-induced alter-
ation in domain IV and the rest of the molecule. The residue
R448 is an exception (Fig. 5). It undergoes pathogenic
mutations to H, G, and C, but in the model R448 is exposed
at the surface and has no interactions with other residues. In
m-calpain, the corresponding R375H expressed in E. coli
was fully active in our in vitro assay. For both R448H and
D705G (see below) it is assumed that the observed muta-
tions do not affect the intrinsic activity of calpain 3, but
must disturb the interaction of calpain 3 with other mole-
cules in vivo.
Domain IV
There are 11 reported pathogenic mutations in this domain
(Fig. 4 D), but the model does not offer clear explanations
in every case. The mutations Q638P (located in a modeled
-helix that is not present in m-calpain), and R698P (also in
an -helix), will cause serious disruption because helices
cannot accommodate a Pro residue. The mutation D705G
involves a key Ca2-chelating residue in EF-hand 2, and
FIGURE 5 The position of R448 in domain III
of the calpain 3 model. This residue is implicated
in LGMD2A but is remote from the neighboring
domains. R448 is thought to be potentially in-
volved in the interaction with other partners.
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might be expected to affect the Ca2 requirement of calpain
3. However the corresponding mutant in m-calpain, D585G,
was fully active, and we have shown elsewhere that other
alterations in EF-hand 2 had very little effect on m-calpain
(Dutt et al., 2000). Owing to the difficulties of preparing
calpain 3, its Ca2 requirement has not been directly mea-
sured.
In conclusion, we have noted that most calpain 3 mis-
sense mutations are clustered in three areas that appear to
affect intramolecular domain interactions and may impair
the assembly and activation of this multi-domain protein. In
particular, the flexibility of domain I is directly affected in
many mutants, and is very likely to impair assembly of the
active site and consequently function of calpain 3. The
pathogenic effects of many missense mutations in calpain 3
can therefore be readily understood in terms of loss of
catalytic activity, and the predictions are supported by ex-
pression of the related mutations in m-calpain. A very high
proportion of the clinically observed mutations involves an
alteration in charge of side chains involved in internal salt
links, changes that are expected to be highly disruptive.
These results also strongly suggest that the proposed model
of calpain 3 is close to correct. There are some mutations,
exemplified by V98I, where the mutation is not predicted to
have much effect on proteolytic capacity; and there are at
least two mutations, R448HGC and D705G, where the
mutation has no effect when expressed in m-calpain. The
clinical consequences of these latter two mutations seem
likely to involve effects in vivo on the interaction of calpain
3 with its substrates or binding targets.
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